Dirk Arnold, MD, PhD, medical director, Asklepios Tumour Biology Centre, discusses a phase 3 clinical trial investigating amivantamab in metastatic colorectal cancer.

Vantive, the former kidney care unit of Baxter, announced plans to invest more than $1 billion in new technology over the ...

Quadruplet therapy is now the accepted standard for patients newly diagnosed with myeloma who are ineligible for transplant; ...

Company to outline vision and showcase foundation for accelerated innovation later this week at 62nd ERA Congress in Vienna, ...

From 2006 and 2016, there were significant reductions in stroke risk among adult patients receiving hemodialysis, which differed by sex and racial group.

AV Access Study to be Presented at the Vascular Annual Meeting (VAM25)DURHAM, N.C., June 02, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company ...

Atacicept ORIGIN Phase 3 trial met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving ...

The data may change how patients are treated following a diagnosis for advanced triple-negative breast cancer, one expert ...

In response to the proposal presented by Fresenius Medical Care, the Subject Expert Committee (SEC) functional under the ...

Prognostic Impact of Prostate-Specific Antigen at 6 Months After Radiotherapy in Localized Prostate Cancer: An Individual Patient Data Analysis of Randomized Trials National estimates of cancer ...

A groundbreaking shift is happening in the treatment of chronic kidney disease thanks to the work of psychologist Mrs. Erika ...

The proposed nomogram demonstrated strong predictive accuracy and clinical usefulness, offering a valuable tool for early ...